Apellis Medical Hub https://validator.w3.org/feed/docs/rss2.html Pegcetacoplan for 52 weeks maintained proteinuria reduction in key patient populations: VALIANT subgroup analyses (NKF Spring 2026 C3G) Low risk for meningococcal infections with systemically administered pegcetacoplan, a C3 and C3b inhibitor (NKF Spring 2026 C3G) Association for Research in Vision and Ophthalmology (ARVO) 2026 GA Longitudinal aqueous humor complement protein dynamics in patients with geographic atrophy receiving intravitreal pegcetacoplan (ARVO 2026 GA) Manuscripts Home Pegcetacoplan for 52 weeks maintains proteinuria reduction and eGFR stabilization for pediatric patients: Phase 3 VALIANT subgroup analysis (PAS 2026 C3G) Clinical efficacy of pegcetacoplan versus iptacopan in patients with C3 glomerulopathy: Indirect treatment comparisons (SWNC 2026 C3G) NKF 2026 Spring Clinical Meetings Geographic Atrophy GA Topographic forecasting of geographic atrophy progression from OCT-derived retinal biomarker maps using a neural ODE framework (ARVO 2026 GA) C3 Glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) First time phase 1 results of APL-3007: A novel systemic C3 siRNA for geographic atrophy secondary to age-related macular degeneration (ARVO 2026 GA) Earlier treatment yields better outcomes: 5-years of pegcetacoplan treatment for geographic atrophy secondary to AMD (ARVO 2026 GA) Geographic Atrophy Geographic Atrophy Risk Calculator VALIANT: One year of pegcetacoplan for C3G or primary (idiopathic) IC-MPGN (ANNA 2026 C3G) Pediatric Academic Societies (PAS) 2026 C3G Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial (SWNC 2026 C3G) American Nephrology Nurses Association (ANNA) National Symposium 2026 C3G Earlier Treatment Yields Better Outcomes: 5 Years of Pegcetacoplan Treatment for Geographic Atrophy Secondary to AMD (Macula Society 2026 GA) PNH Congress Presentations Paroxsymal Nocturnal Hemoglobinuria (PNH) Low Risk For Meningococcal Infections With Systemically Administered Pegcetacoplan, a C3 and C3b Inhibitor (AAMDSIF BMF 2026 PNH) International AAMDSIF Bone Marrow Failure Disease Scientific Symposium (AAMDSIF BMF) 2026 PNH Low Risk For Meningococcal Infections With Systemically Administered Pegcetacoplan, a C3 and C3b Inhibitor (THSNA 2026 PNH) Retina Fellow Research Grant Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis (SWNC 2026 C3G) Pegcetacoplan population pharmacokinetic and exposure-response in pediatric and adult patients with C3G and primary immune-complex membranoproliferative glomerulonephritis (ASCPT 2026 C3G) Cutting Edge of Transplantation (CEoT) 2026 C3G Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis (CEoT 2026 C3G) American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2026 C3G Southwest Nephrology Conference (SWNC) 2026 C3G Macula Society 2026 GA AI in GA: Learnings From the Pegcetacoplan Clinical Program (Macula Society 2026 GA) Can Visual Acuity be Estimated from Multimodal Imaging of Geographic Atrophy in Age-related Macular Degeneration? (Macula Society 2026 GA) Fellow Eye Analysis in Bilateral GA due to AMD: Long-term Data from the OAKS, DERBY, and GALE Studies (Macula Society 2026 GA) Factors Affecting Disease Progression and Vision Loss in Geographic Atrophy: Findings from OAKS and DERBY (Macula Society 2026 GA) Retrospective Comparative Analysis of Demographic and Clinical Profiles in Pegcetacoplan-Treated and Untreated Patients With Geographic Atrophy (Macula Society 2026 GA) Real-World Pegcetacoplan and Anti-VEGF Treatment Patterns Among Patients With Geographic Atrophy (Macula Society 2026 GA) OCT-F: AI-Enabled Retinal Function from Structural OCT – Results from OAKS and DERBY (Macula Society 2026 GA) Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis (NKF SC Medical Symposium 2026 C3G) NKF Southern California Medical Symposium 2026 C3G Clinical efficacy of pegcetacoplan versus iptacopan in patients with C3 glomerulopathy: Indirect treatment comparisons (NKF SC Medical Symposium 2026 C3G) Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalisation (≤0.2 g/g): Phase 3 VALIANT trial (NKF SC Medical Symposium 2026 C3G) Ellipsoid zone loss in isolation and outer nuclear layer are photoreceptor integrity endpoints that predict future visual decline in geographic atrophy (ARVO 2026 GA) Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalisation (≤0.2 g/g): Phase 3 VALIANT trial (NKF SC Medical Symposium 2026 C3G) (Relink to conference page) Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis (WTC 2025 C3G) World Transplant Congress (WTC) 2025 C3G Thrombosis and Hemostasis Summit of North America (THSNA) 2026 PNH Factors affecting disease progression and vision loss in geographic atrophy: Findings from OAKS and DERBY (ARVO 2026 GA)